IAA - Exploitation of Novel Protein Conjugation Chemistry

Project: Research council

Project Details


This project brings together two novel technologies being developed by van den Elsen and Watts, with the aim of commercialising both.

In collaboration with Porton Biopharma Ltd (PBL), we aim to exploit the use of our novel conjugation chemistry (EPSRC supported) to test the utility of Sbi as a vaccine adjuvant in the PBL Anthrax vaccine programme. PBL has a long history in the area of developing Anthrax vaccine (AV) and its second-generation versions, including Anthrax protective antigen (PA) and lethal factor (LF). They have been developing these second-­‐generation vaccines with an adjuvant but none of these have gotten to licensure in the clinic. This collaboration would create a great opportunity to further explore the potential of both our chemical conjugation and Sbi vaccine adjuvant technologies, generating the necessary proof-­‐of-­‐concept data required to commercialise these technologies.

Specifically, the technology developed by the EPSRC-­‐funded studentship is used to chemically conjugate Sbi protein with AV (consisting of a cocktail of 100+ proteins) and the recombinant PA and LF anthrax antigens. This will allow us to manufacture THREE novel vaccine products to be evaluated by PBL.
Effective start/end date1/06/1831/03/20


  • Engineering and Physical Sciences Research Council


  • Impact tracking


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.